EBV Screening for the Early Detection of Nasopharyngeal Carcinoma
The Epstein-Barr virus (EBV) Screening for the Early Detection of Nasopharyngeal Carcinoma (NPC) in China demonstration project includes a group of approximately 30,000 men and women ages 35-69 recruited into the active screening arm of a community-randomized trial to evaluate the impact of EBV-based antibody screening on NPC mortality rates. As part of this effort, NCI is collaborating on a substudy to evaluate the sensitivity and specificity of endoscopy versus MRI for the detection of NPC and the utility of nasopharynx viral load testing to triage EBV antibody positive individuals. Approximately 1,400 individuals who participated in the larger EBV screening program are included in this effort. Participants undergo endoscopy and MRI procedures. When lesions are observed by either method, biopsy specimens are collected for pathological evaluation. Blood and nasopharyngeal swab samples are also collected from participants.